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G protein-coupled receptor (GPCR) kinases (GRKs) are mainly involved in the 
desensitization of GPCRs. Among them, GRK2 has been described to be 
upregulated in many pathological conditions and its crucial role in cardiac 
hypertrophy, hypertension, and heart failure promoted the search for 
pharmacological inhibitors of its activity. There have been several reports of potent 
and selective inhibitors of GRK2, most of them directed to the kinase domain of the 
protein. However, the homologous to the regulator of G protein signaling (RH) 
domain of GRK2 has also been shown to regulate GPCRs signaling. Herein, we 
searched for potential inhibitors of receptor desensitization mediated by RH domain 
of GRK2.  
Materials and methods 
We performed a docking-based virtual screening utilizing the crystal structure of 
GRK2 to search for potential inhibitors of the interaction between GRK2 and Gαq 
protein. To evaluate the biological activity of compounds we measured, calcium 
response of histamine H1 receptor (H1R) using Fura-2AM dye and H1R 
internalization by saturation binding experiments in A549 cells. GRK2(45-178)GFP 
translocation was determined in HeLa cells through confocal fluorescence imaging.  
Key findings 
We identified inhibitors of GRK2 able to reduce the RH mediated desensitization of 
the histamine H1 receptor and GRK2 translocation to plasma membrane. Also 











We obtained compounds with the ability of reducing RH mediated actions of GRK2 
that can be useful as a starting point in the development of novel drug candidates 
aimed to treat pathologies were GRK2 plays a key role. 
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1. Introduction 
G protein-coupled receptor (GPCR) kinases (GRKs) are key regulators of the largest 
family of membrane receptors involved in signal transduction. GPCRs modulate a 
multitude of physiological processes, and their dysregulation contributes to many 
diseases, being the targets of ~35% of Food and Drug Administration approved 
drugs [1]. 
In mammals there have been identified seven members belonging to GRK family of 
proteins which have been classified into three subfamilies according to their amino 
acids sequence and ternary structure homology: visual GRKs (GRK1, and GRK7), 
GRK2 subfamily (GRK2 and GRK3), and GRK4 subfamily (GRK4, GRK5 and 
GRK6). Whereas GRK1 and 7 are specifically expressed in retinal cells and GRK4 in 
testis, the rest of GRKs (GRK2, 3, 5, and 6) are ubiquitously expressed [2–4]. The 
protein structure of GRKs consists of three structural and functional well defined 
domains: an N-terminal domain homologous to the regulator of G protein signaling 
(RH domain) that is involved in receptor recognition, a central highly conserved 
catalytic domain with kinase activity, and a C-terminal domain responsible of 











In particular, GRK2 was originally described to specifically phosphorylate the C-
terminal tails or cytoplasmic loops of active GPCRs, promoting binding of β-arrestin 
proteins to the receptor hence inhibiting interactions with heterotrimeric G proteins 
and further signaling [6]. This process known as homologous desensitization, is an 
adaptive mechanism aimed to prevent receptor overstimulation. There are several 
relevant pathological situations where GPCRs signaling is dysregulated by a variety 
of mechanisms related to GRK2 multifunctional role, indicating the physiological 
importance of this protein in disease progression.  GRK2 levels and activity have 
been reported to be increased in patients or in preclinical models of cardiac 
hypertrophy, hypertension, heart failure, obesity and insulin resistance conditions. 
Accordingly, pharmacological inhibition of GRK2 or genetic deletion proved to be 
cardioprotective in cardiovascular and metabolic diseases [7]. On the other hand, 
alterations in GRK2 levels in immune cells have been described to play an important 
role in the development of inflammation and have been associated to Alzheimer, 
multiple sclerosis and rheumatoid arthritis where GRK2 was proposed as a viable 
therapeutic target [8–11]. In the last decades a growing body of evidence showed 
that GRK2 may also regulate downstream activity of GPCRs independently of 
receptor phosphorylation. Desensitization of GPCRs signaling independently of 
kinase activity has been described  for adenosine type 1 receptor (A1R) and µ-opioid 
receptor (µOR) [12], metabotropic glutamate receptor 5 (mGluR5) [13], histamine H1 
and H2 receptors (H1R and H2R) [14,15], lysophosphatidic acid (LPA1) receptor [16] 
, endothelin receptor type B (ETb) [8] , follicle-stimulating hormone receptor [17] and 
D2 dopamine receptor [18] among others. Even more, direct interaction of GRKs 










some cases expression of the RH domain of GRK2 resulted sufficient for attenuating 
receptor signaling through Gαq activation [20,21].  
Although targeting GRK2 emerges as a potentially relevant approach to treat 
pathological conditions [22,23] the search of selective and potent GRK2 inhibitors 
has presented many difficulties, mainly due to the lack of specific blockage of GRK2. 
While inhibition of the pleckstrin homology domain of GRK2 proved to be a 
successful strategy, most kinase inhibitors acting as ATP-competitive inhibitors 
displayed some degree of activity towards other GRKs or even other members of the 
AGC family of kinases as PKA or ROCK [24]. 
In this work we performed a docking-based virtual screening (DBVS) directed to the 
RH domain of GRK2. We identified candidates that inhibited RH mediated 
desensitization of GPCRs and GRK2 translocation to plasma membrane. Through 
this strategy we achieved novel drug candidates with the ability of interfering with 
phosphorylation independent actions of GRK2 that may be useful for treatment of 
conditions where GRK2 plays a crucial role.  
 
2. Materials and Methods 
2.1. Chemicals and plasmid constructions 
Bovine serum albumin (BSA), fura-2 acetoxymethyl ester (Fura-2AM), histamine 
dihydrochloride, mepyramine, triton X-100 and pluronic acid, were obtained from 
Sigma Chemical Company (St. Louis, MO, United States). CMPD101 was acquired 
from Tocris Cookson Inc. (Ballwin, MO). [3H]mepyramine was purchased from Perkin 
Elmer Life Sciences (Boston, MA). Screening compounds were acquired from 
Enamine Ltd. (Monmouth, NJ).  Fetal calf serum was from Natocor (Argentina). 










pcDNA3-GαqQL was a generous gift from Dr O. Cosso (IFIBYNE, UBA-CONICET, 
Argentina). pcDNA3-GRK2D110A and pcDNA3-GRK2K220R was kindly provided by 
Dr. J. Benovic (Thomas Jefferson University, Department of Microbiology and 
Immunology, Kimmel Cancer Center, Philadelphia, USA). pEGFP-HAGRK2(45-
178)GFP was a generous gift from Dr. P. Wedegaertner, (Thomas Jefferson 
University, Philadelphia, PA, USA). 
The following primary antibodies were purchased from Santa Cruz Biotechnology, 
CA: 
Anti-β-tubulin (IgG from rabbit / catalogue#SC-9104 / Lot#F1210 / final dilution: 
1/500) 
Anti-GRK2 (IgG from rabbit / catalogue#SC-562 / Lot#F1610 / final dilution: 1/1000) 
The secondary antibody Anti-rabbit (IgG from goat / catalogue#PI1000 / Lot#X0126 / 
final dilution: 1/4000) was purchased from Vector Laboratories, CA. 
 
2.2. Conformational analysis 
The human GRK2 crystal structures were retrieved from the Protein Data Bank 
(PDB). A total number of seven conformations, excluding mutants, were used for the 
analysis.  
The z-scores derived from C-alpha RMSD per position of the maximum-pair of 
conformers were calculated using ProFit software and the results were expressed as 
[25]: 
  z-score = RMSD position - RMSD average / standard deviation  
The number of cavities and tunnels, as well as their properties, were estimated for all 
conformers using Fpocket [26]. The solvent accessibility per residue was calculated 










All data obtained were retrieved and processed using our own scripts coded in 
Python. 
 
2.3. Virtual screening and data visualization 
In order to identify potential inhibitors of RH domain of GRK2, we performed a 
docking based virtual screening (DBVS) using an opened conformation of GRK2 
(PDB ID:3KRW_A), with the biologically relevant residues Arg106 and Gln133 
exposed to the solvent.  The database employed in the DBVS was the publicly 
available Enamine Advanced Collection (available online: https://www.enamine.net). 
In this study, the pocket containing the residues Arg106 and Gln133 of the RH 
domain of human GRK2 was used as a target. The docking was centered in the 
alpha carbon of Leu136, with a grid size of 22 Å. AutoDock Vina [28] was used as 
DBVS software. The docking assay for the top hundred compounds was repeated 
one hundred times to confirm the massive screening results. Results obtained with 
AutoDock Vina were also confirmed with Autodock 4.2 [29]. The chemical 
compounds displaying the highest docking scores in the calculations were used for 
the in vitro activity assays. 
 
2.4. Cell culture and transfection 
A549 (human lung carcinoma epithelial cells, ATCC # CCL-185), HepG2 (human 
hepatocellular carcinoma epithelial cells ATCC # HB-8065)  and HeLa (human cervix 
adenocarcinoma epithelial cells, ATCC # CCL-2) cells were cultured in Dulbecco’s 
Modified Eagle's Medium (DMEM) and U937 (human histiocytic lymphoma 










with 10% fetal calf serum and 50mg/ml gentamicin. Cultures were maintained at 
37°C in humidified atmosphere containing 5% CO2. 
For transient transfections, A549 or HeLa cells were grown to 80–90% confluency 
and the cDNA constructs were transfected using the K2 Transfection System 
(Biontex, Munich, Germany). The transfection protocol was optimized as 
recommended by the suppliers. Assays were performed 48 h after transfection. 
 
2.5. Western Blot assays 
For western blot assays, cells were lysed in 50mM Tris–HCl pH 6.8, 2% SDS, 
100mM 2-mercaptoethanol, 10% glycerol and 0.05% bromophenol blue and 
sonicated to shear DNA. Total cell lysates were resolved by SDS-PAGE. Blots were 
incubated with anti-beta tubulin and anti-GRK2 primary antibodies (Santa Cruz 
Biotechnology, CA), followed by horseradish peroxidase conjugated anti-rabbit 
antibody (Vector Laboratories, CA; see materials for details) and developed by 
enhanced chemiluminescence (ECL) following the manufacturer’s instructions 
(Amersham Life Science, England). 
 
2.6. Intracellular calcium measurements 
Changes in intracellular Ca2+ concentration were measured using Fura-2AM 
fluorescent indicator. A549 cells were seeded in 96 wells dishes for 24h (90–100% 
confluence). Thereafter, culture media was replaced by loading buffer (140mM NaCl, 
3.9mM KCl, 0.7mM KH2PO4, 0.5mM Na2HPO4, 1mM CaCl2, 0.5mM MgCl2 10mM 
glucose, 0.1% BSA, 20mM HEPES, pH 7.4) containing 4mM Fura-2AM and 0.2% 
pluronic acid and cells were incubated for 90 min at 37°C in humidified atmosphere 










dye was removed by washing cells with loading buffer. Fluorescence was measured 
in a FlexStation 3 microplate reader (Molecular Devices Inc., San Jose, CA, United 
States). The wavelength was set at 340 and 380 nm, and detection was at 500 nm. 
After 30 s of initial recording to determine basal levels, 100μM Histamine and the 
time course of intracellular Ca2+ mobilization was recorded for 180 s. At the end of 
the time course, Triton X-100 (0.25% v/v) was added to determine Fmax. Basal 
levels (B) were determined as the media of the recorded measurements in the first 
30 s for each well. Autofluorescence was quantified by measuring the fluorescence 
produced by an equivalent suspension of not-loaded cells. Results were expressed 
as the ratio of fluorescence’s 340/380 (X) normalized according to: X´=(X-B)/(Fmax-B) 
For desensitization experiments, A549 cells were treated with 10, 33 or 100μM or 
vehicle histamine in the last 10 min of incubation with the Fura-2AM dye.  Thereafter, 
cells were washed twice with loading buffer and assay proceeded in the same way 
as indicated before. 
For biological activity screening of Enamine compounds, A549 cells loaded with 
Fura-2AM were pretreated with 100nM of C1-C15 or DMSO during 40 min, and 
response and desensitization experiments were performed. 
 
2.7. Internalization assay 
A549 cells were incubated (internalized) or not (control) for 60 min with 100μM 
histamine and after washing, the number of receptor sites was analyzed by 
radioligand-binding assay. CMPD101 10μM or C13Z34 100nM inhibitors were added 
20 min prior to histamine treatment and their concentrations were maintain during 
incubation with histamine. For binding studies, duplicate saturation assays were 










4°C with increasing concentrations of [3H]mepyramine in the absence or presence of 
10µM unlabeled mepyramine. Specific binding was calculated by subtraction of 
nonspecific binding from total binding. The incubation was stopped by washing two 
times with ice-cold saline solution. Experiments on intact cells were carried out at 
4°C to avoid ligand internalization. 
 
2.8. GRK2 translocation assays 
HeLa cells were seeded in 35mm plates and transfected with pEGFP-HAGRK2(45-
178)GFP alone or in combination with pcDNA3-GαqQL. After 24 h, cells were 
seeded in polylysinated glass at 15% confluence and 24 h later cells were starved 
for 4 h and then treated with the indicated compounds at 100nM for 30 min. Cells 
were then washed with PBS, fixed in 4% formaldehyde in PBS for 15 min and 
washed again. Images were examined using an Axio Observer.Z1 microscope (Carl 
Zeiss Microscopy GmbH, Germany; Objetive LCI Plan-Neofluar 63x/1,30 Imm Korr 
DIC M27; Optovar 1x Tubelens; ZEISS Filter set 38 HE ‐ eGFP, BP 470/40, FT 495, 
BP 525/50, and AxioCam HRm3 S/N 631 camera (adaptor 0,63x; exposition time 
500-900ms; focus 0,86μm). Intensity profiles were performed using Image J 
software. 
 
2.9. Cytotoxicity determination assays 
HepG2 and U937 cells were treated with increasing concentrations, ranging from 
333nM to 100μM, of C5Z29, C9Z81, C13Z34 or DMSO during 48hs. Cell viability 
was determined by Trypan Blue exclusion and counting in Neubauer chamber. 
 










Experimental logarithms of capacity factor (log k) were calculated by liquid 
chromatography (HPLC, Waters 590 HPLC Pump) with an ultraviolet detector (320–
336 nm, Jasco-975, Software WinPcChrom XY, Jasco Inc, Easton, MD, USA) and a 
Sunfiret column C18, 5.0 mm, 4.6 x 150 mm (Waters Corp., Milford, MA, USA). 
Stock solutions of each TSC in DMSO (3.5 mg/ml) were injected (10 ml) and a 
mobile phase composed of acetonitrile–buffer phosphate pH 7.0 (29 mM) of different 
volume ratios (20 : 80, 25 : 75, 30 : 70, 40 : 60, 45 : 55, 50 : 50 and 55 : 45) was 
pumped at a flow rate of 1.0ml/min. Logarithms of capacity factor (log k) were 
calculated as follows: 
logk = log[(tr - to)/to]  
Being tr and to the retention time and the dead time (solvent front, DMSO) 
respectively. A curve of log k versus the percentage of acetonitrile (%) in the mobile 
phase was built and log kwater (log kw) values were extrapolated at 0% acetonitrile 
[30]. 
 
2.11. Statistical Analysis 
Numbers (n) for all experiment are provided in corresponding figures and refer to 
independent measurements. Fittings of sigmoidal concentration-response and 
comparison of best fit values according to extra-sum of squares F test were 
performed with GraphPad Prism 5.00 for Windows, GraphPad Software (San Diego, 
CA). 
Statistics were performed using GraphPadInStat version 3.01, GraphPad Software 
(San Diego, CA). Comparisons were made using Two-way ANOVA followed by the 










was no significant variance in homogeneity. Different letters indicate statistically 
significant differences. The level of significance was set at P<0.05. 
 
3. Results 
3.1. In Silico conformational diversity analysis of GRK2 crystallographic 
structures and target selection 
It has been described that action of RH domain of GRK2 depends on the PPI surface 
between GRK2 and the Gαq protein [31]. Based on that, structural analysis of 
biologically relevant pockets and their accessibility was carried out [32] as well as the 
identification of those relative small regions or hot spots, that govern the PPI surface 
since are responsible for the disproportionate contribution to the binding energy 
between the two proteins [33]. 
It is well established that the crystal structures of the same protein from different 
crystallization conditions, are informative about the structural dynamics of the protein 
[34]. Also, it is well known that different protein conformations may differ in the 
number and physicochemical properties of their tunnels and cavities, which is also 
related with the protein functionality [32, 35]. Thus, protein flexibility is a fundamental 
requirement for most biological functions, and indeed, protein functionality is poorly 
understood if only a single structure is considered [36]. In order to take into account 
the protein conformational diversity for the analysis, all the crystal structures of 
GRK2 available in the Protein Data Bank (PDB) were retrieved [37]. After excluding 
those with mutations, a total number of 7 conformers were obtained for the structural 
analysis based on the characteristics of biologically relevant pockets. The number of 
pockets were similar in all conformations, nevertheless some conformations 










area for these residues 68.0% and 130.7% bigger than the mean values for these 
positions within the conformers (75.0 Å2 and 54.6 Å2 respectively, with a mean value 
for all the residues of 32.51 Å2). Such residues were identified as necessary for 
GRK2 binding with Gαq through a mutational analysis [38]. We also calculated the Z-
Scores derived from C-alpha RMSD per position of the maximum-pair of conformers, 
focusing on the residues involved in the RH-Gαq PPI as described in Materials and 
Methods. The Z-Score distribution revealed that residues Arg106 and Gln133, are 
located in a relatively low mobility region within human GRK2 structure, contributing 
to the idea that this zone is an appropriate target for small molecules in order to 
interfere RH-Gαq interaction (Fig. 1a). 
To predict the hot spots that could govern the PPI between GRK2 and Gαq (Fig 1b) 
we used the knowledge-based fade and contacts (KFC) server, which is based upon 
the three-dimensional structure of a PPI complex [39], in this case the one between 
bovine GRK2 and chimera Gαq available in the PDB ID: 2BCJ [41]. According to 
KFC predictions, residues Arg106, Phe109, Asp110, Met114, Lys115, Leu118, 
Ala119, and Gln133 on GRK2 are those who contributes the most to interaction with 
Gαq (Fig 1c, purple font). Some of them proved to be fundamental in the interaction 
between GRK2 and Gαq in experimental assays [40] (Fig 1c, boxed residues). 
These results were considered when defining the specific molecular target for 
inhibitors search on human GRK2 of PDB ID: 3KRW [41] (Fig 1d). 
 
3.2. Virtual Screening  
In order to identify novel PPI inhibitors of the GRK2RH/Gαq interface, we performed 
a DBVS using the library “Advanced Collection from Enamine”, which contains more 










rotatable bonds≤7 (https://www.enamine.net). An opened conformation (PDB ID: 
3KRW), with exposed biological relevant residues, was taken as reference for the 
virtual screening analysis. The grid box was built considering the cavities’ volume 
and drug score information. Cavities which maximized those parameters and 
contained biologically relevant residues were included. As result of DBVS using 
AutoDock Vina [28], a ranking of candidate compounds was obtained. These 
compounds were ordered by docking energy, being preferred those candidates with 
lower values. After visual inspection of the poses of the compounds displaying the 
bests docking scores, we chose 15 of them which were acquired from Enamine (Fig. 
2). 
  
3.3. In Vitro Screening of the Candidate Compounds 
With the aim of determining if the candidate compounds show the desired inhibitory 
effect, we measured whether these molecules were able to inhibit GRK2 mediated 
receptor desensitization. We used as biological model A549 cell line, that 
endogenously expresses GRK2 and histamine H1 receptor (H1R), a Gαq coupled 
receptor that proved to be desensitized by the RH domain of GRK2 [14]. Intracellular 
calcium levels were determined using Fura-2AM dye in naïve cells stimulated with 
the agonist histamine (“response assays”) and in desensitized cells stimulated with 
histamine (“desensitization assays”). For evaluation of receptor response, Fura-2AM 
loaded A549 cells were stimulated with 1μM, 10μM and 100μM histamine (HA). A 
concentration dependent calcium response was observed (Fig. 3a, left panel).  For 
evaluation of receptor desensitization A549 cells were pre-exposed to 10μM and 
100μM HA during 10 min, washed and stimulated with 100μM HA to determine the 










agonist lead to a concentration dependent reduction in calcium response to HA (Fig. 
3a, right panel). Based on these results, stimulus with 100μM HA and pretreatment 
with HA 100μM was chosen for evaluation of compounds in response and 
desensitization experiments respectively. To verify if our system was able to 
evidence an alteration in the function of RH domain of GRK2, we transfected A549 
cell line with a dominant negative mutant of GRK2 that is unable to bind Gαq (GRK2-
D110A). Mutant overexpression (Fig. 3b, right panel) potentiated calcium response 
to HA and almost dampened H1R desensitization increasing calcium response even 
in cells pre-exposed to HA (Fig. 3b, left panel).  
To identify RH inhibitors, A549 cells were incubated during 40 min with candidate 
compounds at 100nM and response and desensitization assays were performed. 
Among the 15 molecules evaluated, 3 of them: C5Z29, C9Z81 and C13Z34, 
significantly increased calcium response to HA in both naïve and desensitized cells 
as compared to vehicle control, where compound C13Z34 led to the greater 
increments on calcium response (Fig.4a). To verify whether these compounds act by 
inhibiting GRK2 RH domain we overexpressed GRK2-D110A which is unable to 
interact with Gαq protein and in consequence should be insensitive to the action of 
compounds only if they act by blocking GRK2 RH interaction with Gαq protein. None 
of the active compounds modified H1R stimulated calcium response in cells 
transfected with GRK2-D110A (Fig. 4b). Moreover, none of the active compounds 
have activity per se over intracellular calcium basal levels at the concentrations 
assayed (Fig. 4c), indicating that the observed effects over calcium levels depends 
on receptor activation regulation mediated by the RH domain of GRK2.  
Since C13Z34 induced a reversion in H1R desensitization, almost restoring calcium 










desensitization experiments were performed. Pretreatment with C13Z34 
concentration-dependently increased calcium response in desensitized cells with a 
pIC50 for GRK2 inhibition of 9.13±0.48 (Fig 5a). Interestingly, in presence of a 
dominant negative mutant of GRK2 lacking phosphorylation activity (GRK2-K220R), 
C13Z34 also increased H1R response by diminishing H1R desensitization indicating 
that its action is preserved even over GRK2 kinase death mutant (Fig. 5b). 
Consistently, pretreatment with CMPD101, a potent and selective inhibitor of GRK2 
and GRK3 kinase activity did not modified H1R calcium response nor inhibited short 
term desensitization of the H1R (Fig. 5c). Since H1R internalization depends on 
GRK2 kinase activity we evaluated whether C13Z34 inhibited a phosphorylation 
dependent mechanism. After 1 h exposure of A549 cells to HA 100μM the number of 
H1R membrane sites diminished to the 65.8±2.2% of control basal levels (Fig. 5d). 
CMPD101 completely abolished H1R internalization restoring membrane receptor 
number to that of untreated cells. Conversely, although C13Z34 significantly inhibited 
H1R internalization (80.5±3.4 vs 65.8±2.2% membrane sites; P<0.05) it was not able 
to restore basal levels P<0.05 (Fig. 5d). 
When the interactions and spatial arrangement of active compounds in the 
druggable pocket was analyzed through the study of the obtained docking poses, we 
found in all cases, close contacts with the protein's residues, including Arg106 and 
Gln133. Consistently with previous results, only compound C13Z34 was able to 
establish H-bonds, being residue Gln133 involved in the interaction (Fig. 5e). 
Correct function of GRK2 requires rapid spatial and temporal regulation. Since GRK2 
is a cytosolic protein that migrates to plasma membrane to exert its desensitizing 
action [42] we evaluate whether our candidates were able to block GRK2 










using HeLa cells transfected with GRK2(45-178)GFP, consisting in the RH domain of 
GRK2 fused to green fluorescent protein. The fluorescence intensity was quantified 
in each image using line intensity profiles across each one of the cells. The presence 
of peaks at the beginning and the end of the profile indicates increased concentration 
of GRK2(45-178)GFP at the cell margins (Fig. 6). As expected, GRK2(45-178)GFP 
showed cytoplasmic localization (Fig. 6a, left panel). However, after coexpression of 
the construct with a constitutively active variant of Gαq protein (GαqQL), GRK2 
redistributed to plasma membrane (Fig.6a, right panel). To verify compounds action, 
HeLa transfected cells were incubated during 30 min with 100nM C5Z29, C9Z81 or 
C13Z34, or vehicle (DMSO). GRK2 redistribution to plasma membrane when GαqQL 
is coexpressed was dampened by C5Z29, C9Z81 or C13Z34 pretreatment, but not 
by compound used as negative control or by the vehicle, DMSO (Fig 6b). 
Finally, we determined relevant pharmacokinetics characteristics of compounds in 
order to obtain preliminary information useful for future optimization of candidates. 
Evaluation of cytotoxicity was carried out in HepG2 and promonocytic U937 cells as 
indicators of hepatic and systemic cytotoxicity. Cells were incubated during 48 h with 
compounds’ concentrations ranging from 333nM to 100μM, and cellular viability was 
determined by trypan blue exclusion and counting in Neubauer chamber. Among 
compounds evaluated, only C9Z81 displayed cytotoxicity in both cell lines killing up 
to the 80% of HepG2 and U937 cells and showing an CC50>500µM and of 
16.8±1.25µM respectively (Fig. 7a). Since lipophilicity may impact in every ADMET 
properties of a molecule, and the logKw reflects the logP of a molecule, we 
determined the experimental logKw of compounds as a lipophilicity indicator, through 














Our results show by first time the identification of a new class of GRK2 inhibitors 
directed to the RH-Gαq PPIs with the capacity to induce a significant inhibition of 
receptor desensitization mediated by RH domain of GRK2.  
GRK2 has been extensively validated as a pharmacological target for heart failure 
and hypertension treatment, and has been proposed as a promising one for other 
medical conditions such as Alzheimer’s and Parkinson’s diseases or even insulin 
resistance and diabetes [43–45]. Based on that, identification of small molecules that 
inhibit GRK2 actions is of great interest to confirm the role that this protein play in 
whole body physiology and for therapeutic purpose.  
Many attempts have been done in order to identify promising GRK2 inhibitors. 
However, clinically useful small molecule inhibitors of GRK2 have yet to be 
described. The natural product balanol exhibits 50- and 100-fold selectivity for GRK2 
over other members of the family; Takeda Pharmaceuticals Inc. 101 (CMPD101) and 
103A exhibit similar potency of inhibition against GRK2 as that of balanol, but they 
have better selectivity for GRK2 over other GRKs and AGC kinases (IC50>2μM) [46]. 
The selective serotonin reuptake inhibitor paroxetine has recently been shown to 
directly interact with the orthosteric site of GRK2 and to inhibit receptor 
desensitization by blocking GRK2-mediated adrenoceptor phosphorylation and 
arrestin recruitment [47] but is a much less potent inhibitor than balanol or the 
Takeda compounds. Based on that it seems like specific inhibition of GRK2 kinase 










additional regulatory domains or subunits, their catalytic cores are highly conserved 
making very difficult to obtain selective inhibitors [48]. 
On the other hand, phosphorylation of GPCRs by GRK2 and subsequent arrestin 
recruitment has been associated to protective signaling in the heart. Moreover, 
GRK2 kinase activity display an inhibitory function over cell proliferation and tumoral 
growth in several models [49]. Based on these observations alternative strategies to 
regulate GRK2 functions are of interest. Moreover, phosphorylation of GPCRs is not 
the only mechanism by which GRK2 may regulate GPCRs signaling. Expression of 
dominant negative mutants of RH domain has been sh wn to produce dramatic 
phenotypes. The expression of a GRK2-D110A mutant devoid in Gαq/11 binding 
increases mGluR5 signaling in response to agonist stimulation in striatal neurons 
[13]. GRK2-D110A partially reversed the quenching effect of GRK2, over inositol 
phosphate generation after histamine type 1 receptor stimulation [14]. GRK2 up-
regulates the basal activity of the epithelial Na+ channel as a consequence of the 
binding of its RH domain the α-subunits of Gαq/11 [50]. In the same way, the RH 
domain of GRK2 proved to be involved in regulation of M1 and M3 mAChR [51,52]; 
mGluR1a glutamate receptor [53]; endothelin-1 A receptor [54] and histamine type 2 
receptor [15]. These results suggest that a small molecule RH inhibitor might provide 
profound effects over GPCRs signaling. 
We carried out a computer-aided drug design to discover new ligands based on 
GRK2 crystal structures. Inhibiting PPIs, such as the one between any member of 
RGS family of proteins and Gα subunits is particularly challenging, predominantly 
due to the size and geometry of the interaction interface that covers 750–1500 Å2 
[55] and the lack of well-defined traditional pockets [56]. However, DBVS directed to 










of GRK2 and the Gαq protein, allowed us the identification of candidates’ inhibitors of 
the RH domain. PPI surface between other members of the RGS family of proteins 
and Gαq was identify as a druggable target in assays for bladder capacity and 
spontaneous bladder muscle contraction. In this system small molecules, BMS-
192364 and BMS-195270, effectively affected the RGS/Gαq complex showing that 
small molecules affecting pathways downstream of GPCR function could represent 
potential new therapies for diseases characterized by inappropriate activation of 
GPCR signaling [57].  
Our in silico screening allowed the reduction of the enormous chemical space to a 
manageable number of hits with the potentiality of binding to the RH domain of 
GRK2 and thus leading to a drug candidate. Molecules disrupting the interaction 
between the RH domain of GRK2 and Gαq should increase the magnitude and/or 
duration of G-protein signaling responses, leading to pronounced physiological 
effects. Therefore, the ability of candidates to inhibit GRK2 action was assessed as 
an increase in the calcium response of a GRK2 desensitized GPCR, the H1R, and 
as a diminished H1R desensitization. The action of compounds over the RH domain 
of GRK2 was confirmed using a dominant negative mutant of the RH domain of 
GRK2 (GRK2-D110A) where active compounds lost their effect. In vitro screening of 
candidates in a cellular context presented the advantage of determining a functional 
biological consequence of GRK2 inhibition instead of a mere interaction of 
compounds with the target which sometimes may not occur or fail in a conserved 
cellular context. However, since we only measured compounds effect over H1R 
regulation and GRK2 translocation we cannot rule out the possibility of interaction of 
compounds with other targets that may affect other pathways not evaluated in the 










Based on the chemical structure of the active compounds and the docking poses, it 
is likely that candidates present simple cyclic systems and amide groups. 
Interestingly, oxygen from amide group in C13Z34 is oriented towards Gln133 at an 
optimal distance to act as a hydrogen bond acceptor of NH from Gln133. Concerning 
that, crystallography of bovine GRK2 in interaction with Gαq shown that hydrogen 
bonds are formed between the side chains of Gαq-Thr260 and GRK2-Gln133 [40].  
The RH domain of GRK2 has been shown to lack significant GTPase activity (GAP). 
Based on that, acceleration of GTP hydrolysis may not be its mechanism of action 
[58,59]. However, it has been described that the RGS family of proteins may also 
regulate signaling by occlusion on Gα of the binding site for effector in a mechanism 
known as effector antagonism [60]. It has been described that the GRK2 RH domain 
binds Gαq more like an effector than an RGS protein [40,59]. In this direction, results 
obtained showed that our inhibitors blocked both Gαq-coupled receptor 
desensitization and constitutively active Gαq mediated translocation of GRK2, 
indicating that GRK2 may bind to and sequester Gαq subunit reducing the pool of 
receptor-regulated G proteins and hence, the effects of agonists leading to receptor 
desensitization. Such mechanism has been described for other members of RGS 
family of proteins regarding µ-opioid and muscarinic M3 receptors desensitization in 
the central nervous system [61, 62]. Interestingly, C13Z34 also affected a 
phosphorylation dependent mechanism as H1R internalization. However, since 
C13Z34 proved to block GRK2 translocation to plasma membrane, this blockage 
may be the cause of the attenuation of internalization rather than an inhibition of 
kinase activity by C13Z34 [31, 63, 64]. 
Finally, we preliminary studied preclinical pharmacology of candidates to obtain 










important cause of drug failure in the clinic. Safety assessment of compounds 
through cytotoxicity assays suggests that our candidates are safe at effective 
concentrations. In the other hand, lipophilicity is a key physicochemical property of 
drugs that impacts not only in their pharmacokinetics, but also in their 
pharmacodynamic and toxicological profile. LogKw values obtained for our 
compounds are within the optimum region of lipophilicity that comprises values from 
1 to 3, contributing to their quality as candidate drugs [65]. 
Our strategy was successful at identifying new compounds that not only showed high 
potency against GRK2 mediated desensitization, but also presented adequate 
ADMET properties. This evidence supports the DBVS approach proposed in this 
work and sets the basis to continue investigating the mechanism of action of these 
candidates through the inhibition of the RH domain of GRK2. 
 
 5. Conclusions 
By docking-based virtual screening we identified inhibitors of the RH domain of 
GRK2. 
Active compounds were able to increase H1R response and reduce the RH 
mediated desensitization of the H1R. 
Inhibitors also blocked GRK2 translocation to plasma membrane and diminished 
GRK2 mediated internalization of H1R.  
Active compounds presented adequate ADMET properties. 
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Figure 1. Selection of specific molecular target in RH domain of GRK2. a. Z-
score calculated by the C-alpha RMSD per position of the maximum-pair of 
conformers. Dotted lines indicate the R106 and Q133 residues. b. Crystal structure 
of bovine GRK2 (RH domain: red, kinase domain: blue, PH domain: yellow ribbons) 
in complex with Gαq subunit (Grey ribbons) corresponding to PDB ID 2BCJ. PPI 
interface between both proteins is indicated through surface representation. c. 
Residues predicted by the KFC Server to be energetically important for the PPI 
occurrence are shown in purple font. Residues that when mutated alter GRK2 
binding to Gαq are in boxes. d. Final location of grid box used for DBVS in crystal 
structure of human GRK2 corresponding to pdb ID 3KRW. 
 
Figure 2. C1-C15 compounds acquired from Enamine. Chemical structures, 
identifier code (Z) and docking score (S) of compounds are shown. 
 
Figure 3. Validation of the cellular model used in biological activity screening 
of selected compounds. A549 cells were loaded with Fura-2AM dye, (λexcitation 
Ca
2+
saturated: 340nm, λexcitation Ca
2+










real time experiments.  At 180s Triton 1.6% was added as a control of effective dye 
incorporation into the cell. Intracellular Ca2+ levels were determined as F340/F380 
normalized respect to basal and maximum values. a. Response assays were 
performed in A549 cells loaded with Fura-2AM by stimulation with increasing 
concentrations of histamine (HA) at 30 s of measurement (left panel). 
Desensitization assays were performed in A549 cells loaded with Fura-2AM by 
pretreatment with increasing concentrations of HA during 10 min, and stimulation 
with 100µM HA at 30 s of measurement (right panel). Data from a single experiment 
is shown and is representative of four independent experiments. (*) P<0.05, (**) 
P<0.01 (***) P<0.005 respect to base line (left panel) or control without treatment 
(right panel). b. A549 cells were transiently transfected with GRK2-D110A plasmid or 
empty vector (Mock) and loaded with Fura-2AM. Both were used to perform 
response and desensitization (with 100µM HA) assays (left panel). Overexpression 
of GRK2 variant was verified by Western Blot (right panel). Data from a single 
experiment is shown and is representative of three independent experiments. (*) 
P<0.05, (***) P<0.005, (ns) no significant differences, respect to Mock control without 
pretreatment. Comparisons were made using Two-way ANOVA followed by the 
Tuke,y´s post-test.  
 
Figure 4. Biological activity of hit compounds: Specific positive modulation of 
calcium response. A549 cells were loaded with Fura-2AM dye, (λexcitation Ca
2+-
saturated: 340nm, λexcitation Ca
2+-free: 380nm) and fluorescence (F) was measured in 
real time experiments.  At 180 s Triton 1.6% was added as a control of effective dye 
incorporation into the cell. Intracellular Ca2+ levels were determined as F340/F380 










2AM were pretreated with 100nM of C1-C15 or DMSO for 40 min, and response and 
desensitization assays were performed. Results for all positive compounds C5Z29, 
C9Z81 and C13Z34; and one example of a negative compound C7Z64 are shown. 
Comparisons were made using Two-way ANOVA followed by the Tukey´s post-test. 
Different letters indicate statistically significant differences. (***) P<0.005 respect to 
control without treatment; (###) respect to desensitized cells in presence of vehicle 
DMSO; (ns) no significant differences respect to vehicle DMSO for control or 
desensitized cells b. A549 cells were transiently transfected with GRK2 D110A 
plasmid, loaded with Fura-2AM and used to perform response and desensitization 
(with 100µM HA) assays. c. Direct effect of compounds over intracellular calcium 
levels was evaluated by stimulation of Fura-2AM loaded A549 cells with 100nM of 
compound or DMSO at 30 s of measurement. Data from a single experiment is 
shown and is representative of three independent experiments. 
 
Figure 5. Biological activity of C13Z34. A549 cells were loaded with Fura-2AM 
dye, (λexcitation Ca
2+-saturated: 340nm, λexcitation Ca
2+-free: 380nm) and fluorescence 
(F) was measured in real time experiments.  At 180 s Triton 1.6% was added as a 
control of effective dye incorporation into the cell. Intracellular Ca2+ levels were 
determined as F340/F380 normalized respect to basal and maximum values. a. A549 
cells loaded with Fura-2AM were pretreated with increasing concentrations of C13 
for 40 min, and desensitization assays were performed (left panel). The maximum 
Ca++ response obtained for each C13Z34 concentration was used to build a 
concentration-response curve (right panel). Data from a single experiment is shown 
and is representative of three independent experiments.  b. A549 cells were 










with Fura-2AM and pretreated with 100nM of C13Z34 or DMSO. Both were used to 
perform desensitization (with 100µM HA) assays (left panel) (*) P<0.05, (ns) no 
significant differences, respect to vehicle DMSO in Mock transfected cells. 
Overexpression of GRK2 variant was verified by Western Blot (right panel). Data 
from a single experiment is shown and is representative of three independent 
experiments. Comparisons were made using Two-way ANOVA followed by the 
Tukey´s post-test. Different letters indicate statistically significant differences. The 
level of significance was set at P<0.05. c. A549 cells loaded with Fura-2AM were 
pretreated with 10µM of CMPD101 or DMSO for 40 min, and response and 
desensitization assays were performed. Data from a single experiment is shown, and 
is representative of three independent experiments. d. A549 cells were pretreated 
with 100nM of C13Z34 or 10µM of CMPD101 for 80 min and with HA 100µM for the 
last 60 minutes, washed and incubated with different concentrations of 
[3H]mepyramine as stated in Materials and Methods. Data represent media ± SEM of 
three independent experiments. e. Ligand binding pockets for the most energetically 
favorable conformation of C13Z34 in GRK2. Druggable pocket identified by Fpocket is 
colored in blue and biologically relevant residues (Arg106 and Gln133) are colored in 
green (left panel). Residues of RGS in close contacts 34 are shown (right panels). 
 
 
Figure 6. Biological activity of hit compounds: Inhibition of GRK2(45-178)GFP 
translocation. a. HeLa cells were transiently cotransfected with GRK2(45-178)GFP 
plasmid  and GαqQL (constitutively active) or empty vector, and fixed after 48hs. 
Subcellular localization was assessed by confocal microscopy. b. HeLa cells were 










transfection cells were treated with 100nM of C5Z29, C9Z81, C13Z34, C7Z64 
(negative control) or DMSO (vehicle control) during 40min and fixed. 
At least 100 cells were examined in three independent experiments. For each cell in 
a given image, a line intensity profile across the cell was obtained. Representative 
intensity profiles are shown in yellow for each condition. 
 
Figure 7. Preliminary profiling of physicochemical and in vitro ADMET 
properties of hit compounds. a. HepG2 (left panel) and U937 (right panel) cells 
were treated with increasing concentrations of C5Z29, C9Z81, C13Z34 or DMSO 
during 48hs, and cell viability was determined by Trypan Blue exclusion test. Data 
represent media ± SD of three independent experiments b. Lipophilicity of hit 
compounds was determined by RP-HPLC as detailed in Methods section. 
Processing of retention time “RT” and dead time “T0” (solvent front, DMSO) for each 
compound is shown. Experimental log Kw values correspond to extrapolations at 0% 
acetonitrile (ACN). 
Journal Pre-proof
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
